Trial Profile
A RANDOMIZED PHASE 2/3 TRIAL OF SCH 54031 PEG12000 INTERFERON ALFA-2b (PEG INTRON, SCH 54031) VS. INTRON A (SCH 30500) IN SUBJECTS WITH NEWLY DIAGNOSED CML (PROTOCOL NOS. C/I98-026)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 12 Jun 2018 New trial record